Joyce A. O’Shaughnessy, MD
The triple-negative breast cancer (TNBC) pipeline is transforming, experts say, with the potential additions of immunotherapy and PARP inhibitors. These agents are being explored both as monotherapy and in combination regimens with standard chemotherapy options.
State of the Science Summit on Treatment of Metastatic Breast Cancer. In an interview, she addressed the key issues in breast cancer discussed at the meeting and shared her expert insight on where TNBC treatment is headed based on recent findings.
OncLive: What are some of the key topics being discussed at this State of the Science Summit?
: It is really nice to have the opportunity to have this summit right after SABCS to get everyone together to talk about the data. We’re talking about the estrogen receptor (ER)–positive patient—particularly focusing on the new data coming out with extended adjuvant endocrine therapy—as well as the premenopausal ER-positive patient and how to optimize that. Then, in metastatic breast cancer, there are new agents such as ribociclib. Of course, we have been using palbociclib (Ibrance). How do we sequence everolimus (Afinitor) for patients? There are a lot of new data in the ER-positive space.
mutation, using circulating tumor DNA? Is that at all clinically useful at this time? It’s really covering local control, ER-positive, HER2-positive, triple-negative, and some of the novel diagnostics. We are really covering the waterfront.
Your talk specifically focused on TNBC. What is important to note in this area?
TNBC is in rapid evolution, and we are going to see some stunning progress in the next few years, fortunately. What are the current data we have with carboplatin or platinum-based agents? What about capecitabine in high-risk patients? Our chemotherapy agents are old friends, but are they really useful in the curative setting?
... to read the full story